The Zhitong Finance App learned that US biopharmaceutical giant Gilead Sciences (GILD.US) released its financial report for the third quarter of 2026 on October 29 (Thursday) local time. Driven by double-digit growth in its flagship HIV drug pipeline, the company's product sales for the quarter increased 13% year over year to 8.3 billion US dollars, exceeding market expectations; “basic business” sales after excluding the COVID-19 drug Veklury (remdesivir) increased 16% year over year to 8.2 billion US dollars, the fastest year-on-year basic business growth rate in more than 10 years. Based on strong performance, the company once again raised its annual sales guidelines.

The Zhitong Finance App learned that US biopharmaceutical giant Gilead Sciences (GILD.US) released its financial report for the third quarter of 2026 on October 29 (Thursday) local time. Driven by double-digit growth in its flagship HIV drug pipeline, the company's product sales for the quarter increased 13% year over year to 8.3 billion US dollars, exceeding market expectations; “basic business” sales after excluding the COVID-19 drug Veklury (remdesivir) increased 16% year over year to 8.2 billion US dollars, the fastest year-on-year basic business growth rate in more than 10 years. Based on strong performance, the company once again raised its annual sales guidelines.